Jasper Therapeutics Inc. (JSPR) Stock Price, Quote & News

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic sp...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 549 1400

Website: jaspertx.com

Address:

2200 Bridge Pkwy, Suite 102, Redwood City, United States

BoardSeatBets Dec. 25 at 7:35 AM

$JSPR The valuation debate now centers on reliability of delivery, with macro volatility magnifying operational missteps. Absent traction, patience will erode.

0 · Reply

Doudiane Dec. 23 at 2:56 PM

$JSPR add, hope this fly to 6 minimum

0 · Reply

TheFollower Dec. 23 at 9:12 AM

$JSPR Added 😎

0 · Reply

UnoffensiveName Dec. 23 at 3:20 AM

$JSPR they do but theyre living in shelters w/ no internet

0 · Reply

CoachHendo Dec. 22 at 7:59 AM

$JSPR LT!

0 · Reply

HodlQueen22 Dec. 19 at 5:53 PM

$JSPR catalyst date approaching…

1 · Reply

Adam_Alsharif Dec. 19 at 4:19 PM

$JSPR can this get back up to 2.2?

0 · Reply

FIREINSP Dec. 16 at 3:22 PM

$JSPR And down she goes again…

0 · Reply

iholdTNXPbutIhateSeth Dec. 15 at 9:52 PM

$JSPR this stock has no community,

0 · Reply

FIREINSP Dec. 15 at 3:06 PM

$JSPR pos...

0 · Reply

Jasper Therapeutics, Inc. (JSPR) Discusses Investigation Into BEACON Study Anomalies and Preliminary ETESIAN Asthma Data Transcript

Dec 2, 2025, 7:00 AM EST - 23 days ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Dec 1, 2025, 4:30 PM EST - 24 days ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

Nov 22, 2025, 11:49 PM EST - 4 weeks ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

DRVN

Nov 17, 2025, 12:13 PM EST - 5 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 6:53 PM EST - 6 weeks ago

JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 9:52 AM EST - 6 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Nov 4, 2025, 8:00 AM EST - 7 weeks ago

Jasper Therapeutics to Present at Upcoming Investor Conferences

Oct 10, 2025, 8:05 PM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper

Sep 22, 2025, 1:05 PM EDT - 3 months ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)

Sep 19, 2025, 12:07 AM EDT - 3 months ago

Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Sep 18, 2025, 4:08 PM EDT - 3 months ago

Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 11, 2025, 12:18 PM EDT - 5 months ago

JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jul 9, 2025, 8:00 AM EDT - 6 months ago

Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Jul 7, 2025, 1:25 PM EDT - 6 months ago

Jasper Therapeutics Shares Fall On Briquilimab Drug Lot Problem

Jul 7, 2025, 7:30 AM EDT - 6 months ago

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

Jun 14, 2025, 10:00 AM EDT - 6 months ago

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Jun 3, 2025, 8:00 AM EDT - 7 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress

May 12, 2025, 4:05 PM EDT - 8 months ago

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 1, 2025, 12:45 PM EST - 10 months ago

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 28, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Feb 27, 2025, 8:00 AM EST - 10 months ago

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 4:30 PM EST - 10 months ago

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Feb 10, 2025, 8:00 AM EST - 11 months ago

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Feb 4, 2025, 4:30 PM EST - 11 months ago

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Jan 8, 2025, 7:00 AM EST - 1 year ago

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jan 6, 2025, 8:00 AM EST - 1 year ago

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Dec 2, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Nov 18, 2024, 10:09 AM EST - 1 year ago

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 13, 2024, 4:30 PM EST - 1 year ago

Jasper Therapeutics to Participate at Upcoming Investor Conferences

Nov 7, 2024, 7:30 AM EST - 1 year ago

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 14, 2024, 9:22 AM EDT - 1 year ago

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Oct 14, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

Sep 10, 2024, 7:30 AM EDT - 1 year ago

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Jun 19, 2024, 8:00 AM EDT - 1 year ago

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

BoardSeatBets Dec. 25 at 7:35 AM

$JSPR The valuation debate now centers on reliability of delivery, with macro volatility magnifying operational missteps. Absent traction, patience will erode.

0 · Reply

Doudiane Dec. 23 at 2:56 PM

$JSPR add, hope this fly to 6 minimum

0 · Reply

TheFollower Dec. 23 at 9:12 AM

$JSPR Added 😎

0 · Reply

UnoffensiveName Dec. 23 at 3:20 AM

$JSPR they do but theyre living in shelters w/ no internet

0 · Reply

CoachHendo Dec. 22 at 7:59 AM

$JSPR LT!

0 · Reply

HodlQueen22 Dec. 19 at 5:53 PM

$JSPR catalyst date approaching…

1 · Reply

Adam_Alsharif Dec. 19 at 4:19 PM

$JSPR can this get back up to 2.2?

0 · Reply

FIREINSP Dec. 16 at 3:22 PM

$JSPR And down she goes again…

0 · Reply

iholdTNXPbutIhateSeth Dec. 15 at 9:52 PM

$JSPR this stock has no community,

0 · Reply

FIREINSP Dec. 15 at 3:06 PM

$JSPR pos...

0 · Reply

11thestate Dec. 12 at 3:07 PM

We dug into the latest $JSPR update — and this part is even more impressive. Highlighting the main points for you all. https://11th.com/cases/jasper-investor-suit

0 · Reply

HodlQueen22 Dec. 12 at 3:05 PM

$JSPR BEACON data is expected very soon…if we can move another $0.30-.50 cents then room to $3.5…not a bad move after positive data from earlier this month.

0 · Reply

gianpinco Dec. 12 at 6:28 AM

$JSPR this turd was $20 not long ago, what a disaster.

1 · Reply

MrCodyHUN Dec. 11 at 3:51 PM

$JSPR Needs to break 1.93 for a pump

0 · Reply

MrCodyHUN Dec. 10 at 5:33 PM

$JSPR The movement is weak, volume is low but 2 bucks is inevitable

0 · Reply

27words Dec. 9 at 7:52 PM

$JSPR pop goes the weasel?

0 · Reply

11thestate Dec. 9 at 6:16 PM

$JSPR investors — the loss speaks for itself. Here’s an update worth your attention: a few days ago, a case was filed against Jasper Therapeutics. We’re tracking it closely so you don’t miss your chance to recover your losses. Be sure to check in — we’ll keep you updated. https://11th.com/cases/jasper-investor-suit

0 · Reply

newbulloh2 Dec. 9 at 4:37 PM

$JSPR new xcur?

0 · Reply

FIREINSP Dec. 9 at 2:58 PM

$JSPR Guess they are going for the ATL...

0 · Reply

elmono Dec. 9 at 11:18 AM

$JSPR $SGMO still the case…but started to nibble. They can’t afford a new failure…so thinking data might surprise

0 · Reply

shehww Dec. 8 at 8:05 PM

$JSPR EoD green...

0 · Reply

MrCodyHUN Dec. 8 at 6:35 PM

$JSPR cmon do something

0 · Reply

Market Cap	50.65M
Revenue (ttm)	0.00
Net Income (ttm)	-71.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	209,600
Avg Vol	1,837,682
Day's Range	N/A - N/A
Shares Out	27.98M
Stochastic %K	63%
Beta	3.06
Analysts	Strong Sell
Price Target	$12.67